Sonoma Pharmaceuticals, Inc. is a global healthcare company, which is engaged in developing and producing stabilized hypochlorous acid (HOCl), products for a range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. The Company's product offerings include Lumacyn Clarifying Mist; Regenacyn Advanced Scar Gel; Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel; Microcyn OTC Advanced Wound & Skin Cleanser; Podiacyn Advanced Everyday Foot Care, MicrocynAH and others. Lumacyn Clarifying Mist is intended for use as a daily skin toner, to soothe and cleanse the skin, reduce redness, and manage blemishes by reducing infection. Podiacyn is intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a range of animal wounds and infections.
BörsenkürzelSNOA
Name des UnternehmensSonoma Pharmaceuticals Inc
IPO-datumJan 26, 2007
CEOMs. Amy Trombly
Anzahl der mitarbeiter168
WertpapierartOrdinary Share
GeschäftsjahresendeJan 26
Addresse5445 Conestoga Court, Suite 150
StadtBOULDER
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl80301
Telefon18007599305
Websitehttps://sonomapharma.com/
BörsenkürzelSNOA
IPO-datumJan 26, 2007
CEOMs. Amy Trombly
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten